Top

The European Journal of Health Economics

Published in:

01-04-2018 | Reply

Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

Authors: Alexander Kuhlmann, J.-Matthias Graf von der Schulenburg

Published in: The European Journal of Health Economics | Issue 3/2018

Excerpt

We thank Professor Gandjour for the interest in our article. His comments [1] show that some findings of our study [2] may require a more detailed explanation considering the complexity of the topic: modeling the effects and cost-effectiveness of vaccines including indirect effects. We are grateful for the opportunity to clarify the issues raised by Gandjour. In the following, we will give a point-by-point reply and present results of additional analyses. …

Gandjour, A.: Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

Kuhlmann, A., von der Schulenburg, J.-M.G.: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur. J. Health. Econ. 18(3), 273–292 (2017). https://doi.org/10.1007/s10198-016-0770-9 CrossRefPubMed

Tregnaghi, M.W., Sáez-Llorens, X., López, P., Abate, H., Smith, E., Pósleman, A., Calvo, A., Wong, D., Cortes-Barbosa, C., Ceballos, A., Tregnaghi, M., Sierra, A., Rodriguez, M., Troitiño, M., Carabajal, C., Falaschi, A., Leandro, A., Castrejón, M.M., Lepetic, A., Lommel, P., Hausdorff, W.P., Borys, D., Ruiz Guiñazú, J., Ortega-Barría, E., Yarzábal, J.P., Schuerman, L.: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children. A double-blind randomized controlled trial. PLoS Med. 11(6), e1001657 (2014). https://doi.org/10.1371/journal.pmed.1001657 CrossRefPubMedPubMedCentral

Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J.-P., Schuerman, L.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae. A randomised double-blind efficacy study. The Lancet 367(9512), 740–748 (2006). https://doi.org/10.1016/S0140-6736(06)68304-9 CrossRef

von Kries, R., Toschke, A.M., Siedler, A.: Population-based nationwide study on invasive pneumococcal infections among children in Germany (1997–2003) (unpublished)

van Hoek, A.J., Andrews, N., Waight, P.A., Stowe, J., Gates, P., George, R., Miller, E.: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J. Infect. 65(1), 17–24 (2012). https://doi.org/10.1016/j.jinf.2012.02.017 CrossRefPubMed

Federal Statistical Office of Germany (Statistisches Bundesamt): Diagnosedaten der Krankenhäuser ab 2000 (2013)

Melegaro, A., Edmunds, W.J.: Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22(31–32), 4203–4214 (2004). https://doi.org/10.1016/j.vaccine.2004.05.003 CrossRefPubMed

Mangen, M.-J.J., Huijts, S.M., Bonten, M.J.M., de Wit, G.A.: The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect. Dis. 17(1), 208 (2017). https://doi.org/10.1186/s12879-017-2302-3 CrossRefPubMedPubMedCentral

10.

Mangen, M.-J.J., Rozenbaum, M.H., Huijts, S.M., van Werkhoven, C.H., Postma, D.F., Atwood, M., van Deursen, A.M.M., van der Ende, A., Grobbee, D.E., Sanders, E.A.M., Sato, R., Verheij, T.J.M., Vissink, C.E., Bonten, M.J.M., de Wit, G.A.: Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur. Respir. J. 46(5), 1407–1416 (2015). https://doi.org/10.1183/13993003.00325-2015 CrossRefPubMedPubMedCentral

11.

Rozenbaum, M.H., Sanders, E.A.M., van Hoek, A.J., Jansen, A.G.S.C., van der Ende, A., van den Dobbelsteen, G., Rodenburg, G.D., Hak, E., Postma, M.J.: Cost effectiveness of pneumococcal vaccination among Dutch infants. Economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ (Clin. Res. Ed.) 340, 2509 (2010). https://doi.org/10.1136/bmj.c2509 CrossRef

12.

Garrison, L.P., Mansley, E.C., Abbott, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report—part II. Value Health 13(1), 8–13 (2010). https://doi.org/10.1111/j.1524-4733.2009.00660.x CrossRefPubMed

13.

Garber, A.M.: Chapter 4: advances in cost-effectiveness analysis of health interventions. In: Handbook of Health Economics, vol. 1. Elsevier, Amsterdam, pp. 181–221 (2000)

14.

Posner, R.A.: The social costs of monopoly and regulation. J. Political Econ. 83(4), 807–827 (1975)CrossRef

15.

Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810–815 (2002). https://doi.org/10.1097/01.inf.0000027926.99356.4c CrossRefPubMed

16.

Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187–195 (2000)CrossRefPubMed

17.

Palmu, A.A., Jokinen, J., Borys, D., Nieminen, H., Ruokokoski, E., Siira, L., Puumalainen, T., Lommel, P., Hezareh, M., Moreira, M., Schuerman, L., Kilpi, T.M.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease. A cluster randomised trial. The Lancet 381(9862), 214–222 (2013). https://doi.org/10.1016/S0140-6736(12)61854-6 CrossRef

Title: Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”
Authors: Alexander Kuhlmann
J.-Matthias Graf von der Schulenburg
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue 3/2018
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-018-0956-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Does socioeconomic status affect lengthy wait time in Canada? Evidence from Canadian Community Health Surveys

Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age

Economic and public health consequences of delayed access to medical care for migrants living with HIV in France

Using compensating variation to measure the costs of child disability in the UK

The socio-economic impact of work disability due to inflammatory bowel disease in Brazil

The effectiveness of a population-based skin cancer screening program: evidence from Germany